News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phase II Clinical Data For Predix Pharmaceuticals's Lead Drug Candidate Show Positive Results In Generalized Anxiety Disorder



6/13/2006 12:55:32 PM

LEXINGTON, Mass.--(BUSINESS WIRE)--June 13, 2006--Predix Pharmaceuticals, which recently announced a definitive agreement to merge with EPIX Pharmaceuticals (Nasdaq:EPIX - News), announced today that a Phase II clinical trial of its lead drug candidate, PRX-00023, showed significantly reduced symptoms and was well-tolerated in the 21 patients with generalized anxiety disorder (GAD) participating in the four-week, open-label study. The results are being presented at the 46th Annual New Clinical Drug Evaluation Unit (NCDEU) meeting in Boca Raton, Fla.

Read at press release


comments powered by Disqus
   
Anxiety

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES